TerminatedNot Applicable

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Stopped: Poor accrual

47 participantsStarted 2005-11

Plain-language summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of malignant mesothelioma * Unresectable disease * Must have received treatment with vatalanib on protocol CALGB-30107 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

What they're measuring

Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)

Timeframe: baseline

Trial details

NCT IDNCT00898547

SponsorAlliance for Clinical Trials in Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2006-03

View on ClinicalTrials.gov More Malignant Mesothelioma trials